TPM Vol. 32, No. S4, 2025
ISSN: 1972-6325
https://www.tpmap.org/

Open Access

THE ROLE OF NANOTECHNOLOGY IN PHARMACEUTICAL DEVELOPMENT

VENU ANAND DAS VAISHNAV[1], DOC. MONIZA NUREZ KHAN[2], DR. PRABAL CHAKRABORTY[3]

[1]ASSISTANT PROFESSOR, DEPARTMENT OF PHARMACY, KALINGA UNIVERSITY, RAIPUR, INDIA.
ku.venuananddas@kalingauniversity.ac.in, 0009-0005-3775-6156
[2]ASSISTANT PROFESSOR, DEPARTMENT OF PHARMACY, KALINGA UNIVERSITY, RAIPUR, INDIA.
ku.monizanurezkhan@kalingauniversity.ac.in, 0009-0004-9879-6445
[3]ASSOCIATE PROFESSOR, NEW DELHI INSTITUTE OF MANAGEMENT, NEW DELHI, INDIA., E-MAIL:
prabal.chakraborty@ndimdelhi.org, HTTPS://ORCID.ORG/0000-0002-0876-6188

ABSTRACT

Numerous NMEs with unfavorable biologic and physicochemical characteristics that result in subpar pharmacokinetics and distribution following in vivo injection were chosen for full-scale development due to their pharmacological and safety findings. These NMEs can be transformed into treatments more rapidly if preformulation studies are designed to provide a dosage form with the right drug delivery mechanism to meet desired pharmacokinetic and toxicological parameters. The molecule's biopharmaceutics and pharmacokinetics can be altered to produce the desired druglike properties by nanoparticulate drug delivery methods. Improved systemic administration potential and site-specific delivery, which lowers unwanted toxicity from nonspecific dispersion, boosts patient compliance, and yields favorable therapeutic outcomes, are two advantages of using nanoparticulate drug delivery techniques.

Keywords: NMEs, enhancing potential, clinical outcomes, nanoparticulate drug

1. INTRODUCTION

One of the most popular topics in science nowadays is nanoscience and nanotechnology, which spark a lot of conjecture. A new paradigm in healthcare could be brought about by the application of nanotechnology to medicine [1]. Using this new field of study, pharmaceutical scientists and physicians are putting a lot of effort into delivering medications, genes, and proteins in order to maximize therapeutic advantages [12]. Novel drug delivery systems promise improved therapeutic efficacy, lower dosage, less frequent administration, and less side effects than standard drug delivery systems [2]. The development of medications by the use of nanotechnology, such as size reduction or physical modification by polymers or chemical moieties to create nanoparticles, or more precisely, nanoconstructs, improves the detection and treatment of serious illnesses like cancer [4]. In terms of entrapment, solubilization, or regulated drug release without the need for chemical conjugation, these nanomedicines are more novel chemical entities than their traditional counterparts from a regulatory perspective [11]. Chemotherapy for cancer has several drawbacks, including lengthy treatment, drug resistance, severe side effects, nonselective cytotoxicity that results in noncompliance, incomplete cure, and quality-adjusted life. Various methods must be used to administer the active ingredient in a "drug delivery" strategy, depending on its toxicity and physicochemical characteristics [6]. Injectable drug carriers have demonstrated the potential to revolutionize the treatment of diseases by regulated medication delivery in both space and time [3]. Nanoparticles' small size and the fact that they are frequently composed of biodegradable materials are two key advantages of using them as medication delivery systems [8]. Particle size is discovered to have a substantial impact on the effectiveness of the majority of drug delivery techniques [10]. The enormous surface area and small particle size of drug nanoparticles contribute to their enhanced solubility and bioavailability [16].

2. BACK GROUND OF THE STUDY

By changing the system, it is feasible to stop endogenous enzymes from breaking down the drug. Furthermore, the optimal formulation is not always offered for widely used oral or injectable medications that are currently available on the market [5].



Figure 1: Nanotechnology in Pharmaceutical Science (source: web)

Novel and inventive carrier systems (nanoparticles) will be needed for products that contain proteins or nucleic acids in order to increase their effectiveness and prevent any instability. Quantum dots (QDs) are semi-conducting structures with sizes ranging from 2 to 10 nm. These nanocrystals are made to glow when they come into contact with light. They have an inorganic semi-conductor core (CdSe) and an organic shell covered in zinc sulfide to improve optical properties. QDs become more soluble in aqueous buffers when a cap is added [13]. The radius of the particle is between 2 and 10 nm. Real-time monitoring, bio-imaging in vitro, and long-term tracking of intracellular activity have all been linked to several advantages. These characteristics include bright fluorescence, broad UV excitation, strong photo-stability, and narrow emission.

3. METHODOLOGY

Regarding tumor targeting, third-generation nanoconstructs can be used for active targeting (receptor-ligand interaction) or passive targeting (second-generation nanovectors). Both approaches are crucial, and drug delivery methods must be created to maximize anticancer medication efficacy while minimizing adverse effects [7].



Figure 2: Application of nanotechnology

Apart from the EPR effect that second-generation nanoconstructs provide, the tumor tissue's inadequate lymphatic drainage also promotes the retention of nanoconstructs and the release of drugs close to the tumor cells. Over the past ten years, a number of novel nanomedicine technologies for cancer treatment have been created and are either undergoing clinical trials or are currently available for purchase.



Figure 3: Gender and Age distribution of primary data source

These nanoparticles are employed in diagnostic and therapeutic settings. Using paramagnetic nanoparticles to target specific organs is an efficient method of organ detection.



Figure 4: Mortality rate of primary data source

Artificial liposomes are created by the self-assembly of amphiphilic phospholipids. The spherical double-layered vesicles that surround an aqueous core domain can range in size from 50 nm to several micrometers, depending on their nature [14]. The general biocompatibility and biodegradability of liposomes are the required biological characteristics. Liposomes are the most often utilized nanosystems for drug delivery in clinical research. They can lessen toxicity and systemic effects while also enhancing drug clearance.

TPM Vol. 32, No. S4, 2025
ISSN: 1972-6325
https://www.tpmap.org/

Open Access



Figure 5: Treatment Outcome

Because liposomes cannot enter cells, drugs are also released into the extracellular fluid. Surface modification can provide stability and structural integrity against a hostile bioenvironment after oral or parenteral delivery [9].

4. Performance analysis

Self-assembled systems by definition achieve thermodynamic equilibrium, whereas polymer nanoparticles can be described as polymer aggregates that are out of it. Determining the degree of equilibrium is crucial.



Figure 6: high-resolution mass spectrum

Polymers must meet the same requirements, which include mixing trials with two populations of varied sizes, dilution studies below the threshold micellar concentration, and the production of the final state by altering the beginning conditions [15]. Additionally, there aren't many morphological differences between these two types of systems; polymer nanoparticles often exhibit an almost homogeneous structure, while block copolymer micelles have a typical core/shell shape.

Table 1: Rotated Factor Matrix

Description	Factor		
	1	2	3
What are the key indicators for evaluating the success of infectious disease prevention and control efforts in schools?	.154	-.011	.889

How can schools and public health authorities collaborate to prevent and respond to infectious disease outbreaks?	-.069	.085	.473
What are the effectiveness and cost-effectiveness of interventions aimed at preventing infectious disease transmission in schools (e.g., vaccination programs, enhanced cleaning protocols)?	-.069	.913	.205
What is the relationship between infectious disease outbreaks in schools and broader community transmission?	-.158	.802	-.150
How do school policies and practices (e.g., vaccination requirements, hand hygiene protocols) influence infectious disease transmission?	.251	.733	.282
What are the risk factors for infectious disease transmission in schools, including environmental, behavioral, and social factors?	.150	.221	-.598
What are the demographic characteristics (e.g., age, sex, socioeconomic status) of students, teachers, and staff affected by infectious diseases in schools?	-.593	.662	.453
How do infectious disease outbreaks vary by school type (e.g., elementary, high school, college), size, and location?	-.048	.762	-.269
What is the incidence and prevalence of infectious diseases (e.g., influenza, norovirus, COVID-19) in schools?	.893	.014	-.051

A block copolymer's lipophilic and lipophobic monomer units combine to create polymeric micelles. Block copolymer vesicles, which essentially share the same structure as liposomes, have been regarded as novel and potential drug delivery vehicles in more recent times. Although liposomes were the first artificial drug carriers employed in nanomedicine, they are known to have a membrane instability problem that causes drug leakage. Block copolymers used for vesicle construction get around this issue by creating a thicker membrane because of their comparatively high molar mass. Furthermore, block copolymers' chemical adaptability provides nearly limitless options for altering the vesicle surface to accommodate various biological goals.

5. CONCLUSION

A surfactant or emulsifying agent is used to emulsify the drug-polymer combination in an aqueous solution to create an oil in water (o/w) emulsion. The stable emulsion is then evaporated by continuously swirling the organic solvent or by lowering the pressure. It was demonstrated that a number of properties regulated the nanoparticles' size range. These include the kind and concentrations of the stabilizer and polymer, as well as the speed of the homogenizer. There are several uses for nanotechnology in the medical industry, making it a promising field. By overcoming the challenges of traditional drug delivery methods, it seized the opportunity to develop COVID-19 vaccines based on lipid nanoparticles, which turned out to be more effective than other traditional vaccinations. The number of FDA-approved nanodrugs must be increased, and more research is required to comprehend how the special qualities of these enchanted particles have changed over time.

REFERENCES

1. Thrall, James H. "Nanotechnology and medicine." *Radiology* 230, no. 2 (2004): 315-318.
2. Jaiswal, H., & Pradhan, S. (2023). The Economic Significance of Ecosystem Services in Urban Areas for Developing Nations. Aquatic Ecosystems and Environmental Frontiers, 1(1), 1-5.
3. Demetzos, Costas. "Pharmaceutical nanotechnology." *Fundamentals and practical applications* (2016).
4. Whitmore, J., & Fontaine, I. (2024). Techniques for Creating, Extracting, Separating, and Purifying Food and Feed Using Microalgae. Engineering Perspectives in Filtration and Separation, 2(4), 28-33.
5. Suttee, Ashish, Gurpal Singh, Nishika Yadav, P. Barnwal, R. Singla, N. Prabhu, and Vijay Mishra. "A review on status of nanotechnology in pharmaceutical sciences." *Int. J. Drug Deliv. Technol* 9 (2019): 98-103.

6. Thomas, L., & Iyer, R. (2024). The Role of Unified Medical Terminology in Reducing Clinical Miscommunication and Errors. Global Journal of Medical Terminology Research and Informatics, 2(3), 12-15.
7. Rai, Mahendra, and Carolina Alves dos Santos, eds. *Nanotechnology applied to pharmaceutical technology*. Cham, Switzerland: Springer International Publishing, 2017.
8. Abdulhaleem, K. N., Mohammed, W. K., Said, S. H., & Hasan, Q. F. (2023). Impact of Rapid Corrosion of Steel Bars on the Flexural Behavior of Reinforced Concrete Beams with Different Mix Proportions. International Journal of Advances in Engineering and Emerging Technology, 14(1), 22–33.
9. Devalapally, Harikrishna, Ananthsrinivas Chakilam, and Mansoor M. Amiji. "Role of nanotechnology in pharmaceutical product development." *Journal of pharmaceutical sciences* 96, no. 10 (2007): 2547-2565.
10. Mehta, I., & Dutta, S. (2024). Intergenerational Cultural Transmission in Rapidly Globalizing Societies. *Progression Journal of Human Demography and Anthropology*, *2*(2), 9-12.
11. Halwani, Abdulrahman A. "Development of pharmaceutical nanomedicines: from the bench to the market." *Pharmaceutics* 14, no. 1 (2022): 106
12. Khyade, V. B. (2019). Influence of Sibinin on DMBA Induced Hepatotoxicity and Free-Radical Damage in Norwegian Rat, Rattus norvegicus. *International Academic Journal of Innovative Research*, *6*(1), 20–36. https://doi.org/10.9756/IAJIR/V6I1/1910002
13. S Thakur, Ram, and Ruchi Agrawal. "Application of nanotechnology in pharmaceutical formulation design and development." *Current Drug Therapy* 10, no. 1 (2015): 20-34.
14. Ahmad, Moghis U., Shoukath M. Ali, and Imran Ahmad. "Applications of nanotechnology in pharmaceutical development." In *Lipids in nanotechnology*, pp. 171-190. AOCS Press, 2012.
15. Anand, Anubhav, Preety Gautam, and Smriti Ojha. "Application of nanotechnology for herbal medicine development: A review." *Letters in Drug Design & Discovery* 21, no. 8 (2024): 1325-1333.
16. Mazayen, Zaed M., Amira M. Ghoneim, Rasha S. Elbatanony, Emad B. Basalious, and Ehab R. Bendas. "Pharmaceutical nanotechnology: from the bench to the market." *Future journal of pharmaceutical sciences* 8, no. 1 (2022): 12.
17. Sadulla, S. (2024). Techniques and applications for adaptive resource management in reconfigurable computing. SCCTS Transactions on Reconfigurable Computing, 1(1), 6-10. https://doi.org/10.31838/RCC/01.01.02
18. Carlos, A., José, D., & Antonio, J. A. (2025). Structural health monitoring and impact in civil engineering. Innovative Reviews in Engineering and Science, 3(1), 1–8. https://doi.org/10.31838/INES/03.01.01
19. Vijay, V., Pittala, C. S., Usha Rani, A., Shaik, S., Saranya, M. V., Vinod Kumar, B., Praveen Kumar, R. E. S., & Vallabhuni, R. R. (2022). Implementation of Fundamental Modules Using Quantum Dot Cellular Automata. Journal of VLSI Circuits and Systems, 4(1), 12–19. https://doi.org/10.31838/jvcs/04.01.03
20. Rahim, R. (2024). Energy-efficient modulation schemes for low-latency wireless sensor networks in industrial environments. National Journal of RF Circuits and Wireless Systems, 1(1), 21–27.
21. Prasath, C. A. (2025). Adaptive filtering techniques for real-time audio signal enhancement in noisy environments. National Journal of Signal and Image Processing, 1(1), 26–33.
22. Poornimadarshini, S. (2025). Robust audio signal enhancement using hybrid spectral-temporal deep learning models in noisy environments. National Journal of Speech and Audio Processing, 1(1), 30–36.
23. Kazi, N. (2024). Comparative analysis of AI models for channel estimation in mmWave massive MIMO systems for 6G. Electronics, Communications, and Computing Summit, 2(3), 40–48.